Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials
Potential future drug lag and increases of unapproved drugs were expected to increase. Since the inclusion of Japan in MRCTs results in shorter or no approval lag, Japan should promote to make circumstances where small overseas companies can include Japan in MRCTs.
Authors
- Taro Shibata
- Kenichiro Shiga
- Toshio Miyata (ORCID: https://orcid.org/0000-0001-9153-5024)
Institutions
- Waseda University (JP)
- Johnson & Johnson (Brazil) (BR)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1007/s10147-025-02756-8
- Citations
- 3
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- Waseda University
- Tokyo Women's Medical University